• A confirmed pathological complete response (pCR) recorded in the ACCENT trial
• pCR is extremely rare in advanced pancreatic cancer patients
• pCR means no signs of cancer in tissue examined by a pathologist following surgery

Amplia Therapeutics Limited (ASX: ATX) has announced important new data from its ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the company's best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane in patients with metastatic pancreatic cancer. A patient from the trial has now recorded a pathological complete response (pCR), an extremely rare observation in this patient population. During routine assessment, it was noted that there had been a significant reduction in the size and number of hepatic metastases and in the primary tumour in the pancreas. Surgery was performed to remove both the secondary tumours in the liver and the primary tumour in the pancreas, and pathological examination determined that the removed lesions contained no live tumour tissue, classified as a pCR. A pCR is very rarely reported in patients with advanced pancreatic cancer, where the disease has spread to other organs. In patients with locally advanced (non-metastatic) pancreatic cancer, around 5% of patients do record a pCR in response to neoadjuvant chemotherapy, and this is associated with improvements in overall survival.

Amplia CEO and MD Dr Chris Burns commented: 'We are extremely excited to learn that a patient from our study has achieved a pathological complete response. This is wonderful news for the patient and the clinical team involved. We firmly believe this outcome further demonstrates the promising activity narmafotinib, on top of standard-of-care, is showing in the treatment of advanced pancreatic cancer.'